The Canary Islands Agency of Research, Innovation and Information Sciences (2017-2020, 70,000 €). (ProID2017010101 – “Enfermedad de Alzheimer: hacia un nuevo abordaje genético, molecular y celular”). A novel genetic, molecular and cellular approach to combat Alzheimer’s disease.
Our main goal is to identify and validate pro-synaptic tools with the potential to be used as therapies in human neurodegenerative diseases. In both animal models, overexpression of the phosphoinositide-3-kinase (PI3K) synaptogenic tool will take place early in the development to increase the number of synapses, and to restore sensory and neuronal deficits generated after genetically and pharmacologically induced neurodegeneration. Using genetic and molecular tools in Drosophila melanogaster and transgenic mouse models, we analyse the effect of increasing the number of synapses in vivo in animal models during the early onset of Alzheimer’s disease (AD), characterized by the extensive loss of Synaptic Connections.
Elena Quintana, PhD ACIISI (Postdoctoral Researcher, The Canary Islands Agency for Research, Innovation and Information Sciences, ACIISI, ProID2017010101, ULL).Contracted Lecturer, Doctor in Physiology, Department of Basic Medical Sciences, ULL
0 kommentar(er)
